JPRN-UMIN000026201
Not yet recruiting
未知
Clinical research of the effect and the safety with 0.1% bromfenac sodium hydrate ophthalmic solution and 0.1% betamethasone sodium phosphate ophthalmic, otic and nasal solution in patients with diabetic macular edema - The effect and the safety with 0.1% bromfenac ophthalmic solution and 0.1% betamethasone ophthalmic solution in patients with diabetic macular edema
Diabetes Center Tokyo Womens Medical University School of Medicine0 sites20 target enrollmentFebruary 18, 2017
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Diabetes Center Tokyo Womens Medical University School of Medicine
- Enrollment
- 20
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •On screening (1\)Topical 1\)Patients with severe diabetic retinopathy or DME who need IVT injection of VEGF inhibitor, retinal photocoagulation, or vitreous surgery 2\)Patients with a history of hypersensitivity against components of test drugs 3\)Patients with retinochoroidal disease except for diabetic retinopathy or DME 4\)Patients with uveitis 5\)Patients with glaucoma 6\)Patients with previous vitreous surgery 7\)Patients who received retinal photocoagulation or cataract surgery within 6 months before starting administration of test drugs 8\)Patients who received systemic or topical administration of steroid, IVT injection of VEGF inhibitor within 1 month, or hyperbaric oxygen therapy within 6 months before starting administration of test drugs 9\)Patients with excessive myopia less than \-6D 10\)Patients with a history of hypersensitivity against fluorescein for fluorescent fundus angiography 11\)Patients unable to tolerate OCT measurement (2\)Systemic 12\)Patients with cancer, severe hepatopathy ,nephropathy, cardiovascular disease, or endocrine system disease, who was judged to be inappropriate as a subject by doctor in charge 13\)Pregnant, lactating, or possible pregnant woman On screening and baseline (1\)Topical 14\)Complete loss of ELM or IS/OS line in macular OCT tomography with the eye for effect evaluation 15\)Patients with subretinal fluid in macular OCT tomography 16\)Patients who has cloudy cyst with possible influence to improvement of visual acuity in macular OCT tomography (3\)Other 17\)Patients who was judged to be inappropriate as a subject by doctor
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Clinical investigation of Topaz hair strengthening solution in preventing and improving hair lossHair loss.Nonscarring hair loss, unspecifiedL65.9IRCT20210130050179N5Qeshm Rojin Company20
Recruiting
Phase 2
Clinical investigation of the safety and effectiveness of Excilia Hair strengthening and ani hair loss Lotion in improving hair lossHair loss.Nonscarring hair loss, unspecifiedL65.9IRCT20210130050179N6Zist orchid pharmed Company25
Completed
Not Applicable
A clinical study of the Safety and effectiveness of Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) treatment for the palliation of painful bone metastasesJPRN-UMIN000012441Department of Orthopaedic Surgery, Kochi Medical School, Kochi University25
Not yet recruiting
Phase 4
Clinical Study on the Effectiveness and Safety of Guanxinning Tablets on Coronary Heart Disease Complicated with Diabetic NephropathyITMCTR2100005416Affiliated Hospital of Hangzhou Normal University
Completed
Not Applicable
The evaluation of the clinical effect and safety of stereotactic body radiationtherapy for hepatocellularcarcinomaJPRN-UMIN000016834Hiroshima university100